SCHEMBL6315474

SCHEMBL6315474

Cn1c(=O)c2nc(/C=C/c3ccccc3)cnc2n(C)c1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.53
HSD17B10 Q99714 2/20 0.53
LMNA P02545 2/20 0.53
CASP1 P29466 1/20 0.53
CASP7 P55210 1/20 0.53
ALDH1A1 P00352 5/20 0.50
GAA P10253 3/20 0.50
MEN1 O00255 1/20 0.50
USP2 O75604 1/20 0.50
RECQL P46063 1/20 0.50
KMT2A Q03164 1/20 0.50
HPGD P15428 2/20 0.46
GLA P06280 1/20 0.46
RAB9A P51151 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
ADORA2A P29274 2/20 0.44
MAOB P27338 1/20 0.44
NPC1 O15118 2/20 0.43
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5440337 1.00 KDM4E (0.53) KDM4EHSD17B10LMNACASP1CASP7
SCHEMBL6321029 0.90 KDM4E (0.50) KDM4EHSD17B10LMNACASP1CASP7
SCHEMBL6316381 0.89 KMT2A (0.46) KDM4EHSD17B10LMNACASP1CASP7
SCHEMBL6316300 0.88 KDM4E (0.44) KDM4EHSD17B10LMNACASP1CASP7
SCHEMBL5442970 0.84 MAOB (0.49) KDM4EHSD17B10LMNACASP1CASP7
SCHEMBL5434551 0.81 MAPT (0.41) KDM4EHSD17B10LMNACASP1CASP7
SCHEMBL6314712 0.79 ALDH1A1 (0.49) KDM4EHSD17B10LMNACASP1CASP7
SCHEMBL6322883 0.79 KMT2A (0.46) KDM4EHSD17B10ALDH1A1GAAMEN1
SCHEMBL6315381 0.78 ALDH1A1 (0.43) KDM4EHSD17B10LMNACASP1CASP7
SCHEMBL6314656 0.76 KDM4E (0.45) KDM4EHSD17B10LMNACASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6946465-B2 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2005-09-20 US claimed
US-20030236255-A1 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2003-12-25 US claimed
EP-1187615-A2 IMMUNOSURPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES K.U. Leuven Research & Development (BE) 2002-03-20 EP claimed
WO-2000045800-A2 IMMUNOSURPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) 2000-08-10 WO claimed
US-6946465-B2 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2005-09-20 US disclosed
US-20030236255-A1 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2003-12-25 US disclosed
EP-1187615-A2 IMMUNOSURPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES K.U. Leuven Research & Development (BE) 2002-03-20 EP disclosed
WO-2000045800-A2 IMMUNOSURPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) 2000-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236255-A1 Immunosuppressive effects of pteridine derivatives TPMT, FKBP5, RRP15 KDM4E 1278/4885HSD17B10 3654/4885LMNA 3699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.